

REVIEW ARTICLE

Key role for ubiquitin protein modification in TGF β signal transduction

MIRIAM DE BOECK¹ & PETER TEN DIJKE^{1,2}

¹Department of Molecular Cell Biology and Centre for Biomedical Genetics, Leiden University Medical Center, Postbus 9600, 2300 RC, Leiden, The Netherlands, and ²Uppsala University and Ludwig Institute for Cancer Research, Box 595, 75124, Uppsala, Sweden

Abstract

The transforming growth factor β (TGF β) superfamily of signal transduction molecules plays crucial roles in the regulation of cell behavior. TGF β regulates gene transcription through Smad proteins and signals via non-Smad pathways. The TGF β pathway is strictly regulated, and perturbations lead to tumorigenesis. Several pathway components are known to be targeted for proteasomal degradation via ubiquitination by E3 ligases. Smurfs are well known negative regulators of TGF β , which function as E3 ligases recruited by adaptors such as I-Smads. TGF β signaling can also be enhanced by E3 ligases, such as Arkadia, that target repressors for degradation. It is becoming clear that E3 ligases often target multiple pathways, thereby acting as mediators of signaling cross-talk. Regulation via ubiquitination involves a complex network of E3 ligases, adaptor proteins, and deubiquitinating enzymes (DUBs), the last-mentioned acting by removing ubiquitin from its targets. Interestingly, also non-degradative ubiquitin modifications are known to play important roles in TGF β signaling. Ubiquitin modifications thus play a key role in TGF β signal transduction, and in this review we provide an overview of known players, focusing on recent advances.

Key words: BMP, DUB, E3 ligase, proteasome, signaling, Smad, Smurf, TGF β , TRAF6, ubiquitin

Introduction

One of the major regulators of cell communication in all multicellular organisms is transforming growth factor β (TGF β). TGF β is the prototypic family member of 33 secreted, structurally related human cytokines. They are involved in the regulation of cell proliferation, differentiation, apoptosis, and motility of diverse cell types. Whereas practically all human cell types respond to TGF β , the actions of certain family members are more cell type-selective. The importance of proper TGF β signaling is highlighted by the observation that perturbed TGF β signaling results in tumorigenesis, and many different mutations or other alterations in TGF β signaling components have been identified in human cancers. Intriguingly, TGF β plays a dual role in cancer development and progression. During the early stages of

tumorigenesis, TGF β acts as a tumor-suppressor by inhibiting proliferation. Later in cancer progression, TGF β has pro-angiogenic and immunosuppressive effects, and it promotes metastasis by inducing epithelial to mesenchymal transition (EMT). Cancer cells that manage to evade the anti-proliferative effects of TGF β and simultaneously maintain the tumor-promoting effects benefit from this distorted signaling. The wide variation in cellular responses to TGF β demonstrates the complexity of the intracellular signaling pathways. By studying TGF β signaling and its cross-talk to other pathways, we gain insight into the regulation of cell behavior and consequently in the mechanisms underlying cancer development. In this review we will focus on the regulation of TGF β signaling by the ubiquitin system. We will discuss several mechanisms by which TGF β pathway components are targeted for degradation as a way of

negative regulation. Yet TGF β signaling can also be enhanced via the degradation of negative regulators, and ubiquitination even plays a crucial part downstream of TGF β in various cross-talk pathways. Furthermore, the roles of deubiquitination and non-degradative ubiquitination will be discussed. Finally, we will touch upon the opportunities these regulatory mechanisms give us for pharmacological intervention.

Transforming growth factor β signaling

The TGF β family of cytokines consists of many members including bone morphogenetic proteins (BMPs), growth and differentiation factors (GDFs), and activins. TGF β ligands signal through receptors and Smads and regulate target gene transcription (Figure 1). The differential expression of co-activators and co-repressors in the various cell types gives rise to the wide range in cellular responses. Besides regulating gene transcription through Smad signaling, TGF β can also activate various non-Smad pathways (1,2). Some of these pathways operate independently of Smads; yet others co-operate or even interfere with Smad signaling. The p38 and Jun N-terminal kinase (JNK) mitogen-activated protein

(MAP) kinase pathway is activated upon TGF β stimulation via the ubiquitin ligase tumor necrosis factor (TNF) receptor-associated factor 6 (TRAF6) and TGF β activated kinase 1 (TAK1). TGF β can also activate the Ras-Erk-MAPK pathway, depending on cellular context. This pathway stimulates TGF β -induced EMT, yet it competes with Smad-dependent signaling in regulating cell proliferation. Other pathways affected by TGF β include RhoA-Rock and the phosphoinositide 3-kinase (PI3K)-Akt pathway.

Since TGF β signaling is important for a wide variety of cell functions, it must itself be tightly regulated. It cannot simply be regarded as an on/off switch, because both signal strength and duration are important factors affecting the cellular response outcome. The cellular response to TGF β is highly dependent on the expression levels of receptors (3), Smads, transcription factors, and other signal regulators. Phosphorylation is an important modification in signaling pathways; therefore dephosphorylation is involved in regulating signal transduction as well. And finally, as the abundance of specific proteins and the half-life of activated signaling molecules are crucial for determining the response, targeted




Figure 1. The transforming growth factor β (TGF β) pathway. TGF β ligands function as dimers and signal through type I and type II serine/threonine kinase receptors. Upon ligand binding, the receptors form heterotetrameric complexes allowing the type II receptors to phosphorylate and activate the type I receptors. Subsequently, receptor-activated Smads (R-Smads) are recruited to the type I receptors and phosphorylated. The activated R-Smads associate with the Co-Smad, Smad4, and this heteromeric complex translocates to the nucleus to participate in the transcriptional control of specific target genes (94). TGF β can also activate various non-Smad signaling pathways.

protein degradation is indispensable for regulating cell sensitivity and signal duration. A major pathway to achieve this is the ubiquitin-proteasome system.

The ubiquitin system

Ubiquitination is a post-translational modification of proteins, which can affect their stability, activity, and cellular localization. Ubiquitin (Ub) is a small, 8.5 kDa, protein that is conjugated onto target proteins via its C-terminal glycine (Gly76) residue. Ub is produced in a precursor state of linear chains of Ub moieties or fused to ribosomal proteins. The activity of deubiquitinating enzymes (DUBs) is required to produce free Ub, either by processing precursor Ub or by recycling Ub by removing it from its targets (4). The activity of E1 activating enzymes, E2 conjugating enzymes, and E3 ubiquitin ligases is necessary to conjugate ubiquitin onto its substrates (5). Functional differences between the many different E2 and E3 enzymes lead to substrate and chain specificity. Ub can be conjugated as a single moiety (mono-ubiquitination), or it can form chains, using all internal lysines (K), including K11, K48, and K63 (Figure 2), or a head-to-tail linear chain. All ubiquitin chains, with the exception of K63 chains, have been described to target proteins for proteasomal degradation, thereby regulating their stability. Furthermore, linkage-specific ubiquitin chains have been shown to affect protein-protein interactions and can thereby regulate protein function (6).

E3 ligases display both substrate and chain specificity. While one E3 ligase may preferentially target its substrates for degradation via K48 Ub chains, another may regulate the localization of its targets via mono-ubiquitination. Directly opposing the conjugating function of E3 ligases are the deubiquitinating enzymes (DUBs). DUBs are proteases that remove Ub moieties from their targets. In case of the K48 Ub chain-mediated proteasomal degradation pathway, DUBs remove the Ub chain and stabilize the protein. DUBs also show substrate and chain specificity and therefore represent another layer of regulation of the ubiquitin system.

Negative regulation of TGF β signaling by the ubiquitin-proteasome system

TGF β induces the expression of various genes, among which are negative regulators, such as I-Smads (7,8) and Smurfs that function in a feedback mechanism. Smurfs are HECT (homologous to the E6-accessory protein C-terminus)-type E3 ligases that are known regulators of the TGF β pathway. E3 ligases regulate their own abundance via autoubiquitination.

Under steady-state conditions, Smurf2 inhibits its own ubiquitinase activity and is thereby stabilized (9). Upon binding of Smad7, Smurf2 becomes activated. When TGF β signaling is active, interacting Smurfs and I-Smads are exported from the nucleus to the cytoplasm. I-Smads recruit Smurfs to the active TGF β receptor complexes, and Smurfs target the complexes for degradation (10–12). CD109 has recently been identified as a negative regulator of TGF β signaling by enhancing receptor ubiquitination, in a ligand-dependent manner, by Smurf2 and Smad7 (13,14). The E3 ligases WWP1 (WW domain-containing protein 1) and NEDD4-2 (neural precursor cell expressed, developmentally down-regulated 4–2) have also been shown to be recruited to TGF β receptor complexes by Smad7 (15,16). The subsequent ubiquitination and degradation of the receptors leads to an inhibition of all downstream pathways.

Smurfs also regulate the canonical TGF β pathway at the level of Smad signaling. Smurf1 was shown to ubiquitinate Smad1 and Smad5 (11,17), while Smurf2 ubiquitinates Smad1 and Smad2 under steady-state conditions (18,19). The abundance of Smad1 and Smad3 is also regulated by the E3 Ub ligase U-box-containing carboxyl terminus of Hsc70-interacting protein (CHIP) (20,21). For Smad3, it was shown that a complex of Axin and glycogen synthase 3- β (GSK3 β) affects the ubiquitination, thereby linking R-Smad levels to other cellular pathways in which Axin/GSK3 β function (22). These ubiquitin-mediated degradation pathways are important for controlling the sensitivity of the cell to TGF β by adjusting the absolute and relative abundance of different Smads before the initiation of signaling.

In the presence of TGF β , the active receptor complexes phosphorylate R-Smads, which signal in the nucleus. To limit signaling by Smad complexes, the phosphorylation of R-Smads increases their susceptibility to ubiquitination by E3 ligases such as Smurfs. Phosphorylated Smad1 is subsequently phosphorylated by MAP kinase and GSK3 β (23) to increase its ubiquitination by Smurf1. Also Smad2 becomes more susceptible to ubiquitination by Smurf2 after phosphorylation. Pin1 interacts with phosphorylated Smad2 and Smad3 and enhances their ubiquitination by Smurf2 (24). Phospho-Smad2/3 are also targeted for degradation by NEDD4L (25). Furthermore, Smad3 is targeted for degradation by ROC1-SCF^{Fbw1a}, and this is dependent on TGF β (26). In the nucleus, R-Smads are phosphorylated by CDK8 and CDK9 to enhance transcription, yet these modifications increase Smad ubiquitination (27). The subsequent phosphorylations on activated R-Smads by several kinases regulate the affinity for E3 ligases and therefore the half-life of activated Smads (28). E3 ligase




Figure 2. The ubiquitin system. A: Free ubiquitin is bound by the active cysteine residue of an E1 ubiquitin-activating enzyme, and this process requires ATP. Next, Ub is transferred onto the active cysteine of an E2 ubiquitin-conjugating enzyme. Finally, Ub is transferred onto a lysine residue of the target protein by an E3 ubiquitin ligase. Ubiquitin can be conjugated as mono-ubiquitin (B) or in chains such as K63 chains (C) or K48 chains (D), the last-mentioned known for targeting substrates for proteasomal degradation.

Arkadia was shown to ubiquitinate phospho-Smad2/3, even though Arkadia is generally regarded as a positive regulator of TGF β signaling (see below). Phospho-Smad2/3 are polyubiquitinated by Arkadia after the initiation of target gene transcription, and therefore this ubiquitination step may function to efficiently terminate signaling (29).

The Co-Smad, Smad4, is required for Smad-mediated transcriptional control. By regulating the availability of Smad4, the intracellular response to TGF β and BMP can be controlled. Various E3 Ub

ligases have been identified that target Smad4 for degradation. Similar to R-Smads, Smad4 can be ubiquitinated by Smurfs, WWP1, and NEDD4-2 recruited by Smad7 (30). Binding of Jab1 induces the ubiquitination and degradation of Smad4 (31). CHIP and SCF ^{β -TrCp1} can also conjugate poly-ubiquitin chains onto Smad4, which leads to its degradation and an inhibition of signaling (32,33). The importance of proper regulation of the ubiquitin-mediated proteasomal degradation of Smad4 becomes clear in many human cancers where Smad4 is often lost. Mutations in Smad4 can lead to an

increase in ubiquitination and therefore render the protein unstable (34,35).

As TGF β signaling progresses, the expression of many negative regulators, such as Smurfs, is induced, and higher protein levels of these E3 ligases increase the degradation rate of the receptors and Smads, thereby terminating signaling. Yet the ubiquitin system is also an ideal mediator of cross-talk between signaling pathways. Different signals induce the expression of I-Smads and thereby inhibit TGF β signaling, but pathways can also modulate TGF β signaling directly by recruiting the ubiquitin system. Estrogen was shown to inhibit TGF β signaling by promoting proteasomal degradation of Smad2/3 by Smurf1. Estrogen receptor α directly recruits Smurf to Smads, and this pathway represents direct inhibitory cross-talk mediated by ubiquitin protein modification (36).

Positive regulation of TGF β signaling by the ubiquitin-proteasome system

An important E3 ligase for the enhancement of TGF β signaling is Arkadia. Arkadia was identified as a positive regulator of Nodal signaling, a TGF β family member. Arkadia targets its substrates for proteasomal degradation. Known targets for Arkadia include Smad7 (37), c-Ski, and SnoN (38), all negative regulators of TGF β signaling (Figure 3). Smad7 was already described to

recruit various E3 ligases to the TGF β receptors and Smads, yet it also inhibits TGF β signaling directly by inhibiting the interaction of R-Smads with the receptor complexes (7). C-Ski and SnoN inhibit Smad signaling in the nucleus by disrupting the interaction of Smads with transcriptional co-activators and by inducing inactivation of Smad complexes (39,40). They are also responsible for repressing transcription in the absence of TGF β (41). Upon TGF β signaling, phospho-Smads translocate into the nucleus and recruit Arkadia, but also other E3 ligases such as Smurf2 (42) and anaphase-promoting complex (APC) (43), to induce the ubiquitination of c-Ski and SnoN. The ubiquitination of c-Ski was found to be enhanced by the association of RB1-inducible coiled-coil 1 (RB1CC1) with Arkadia (44). The degradation of Smad7 by Arkadia is enhanced by Axin, a scaffold protein known for its function in Wnt signaling. Wnt negatively regulates Axin, thereby also inhibiting the ubiquitination of Smad7 and thus impacting TGF β signaling (45). By ubiquitinating negative regulators, Arkadia stimulates TGF β signaling.

More examples of positive regulation of TGF β signaling via proteasomal degradation of negative regulators have been identified. TGF β -induced factor 1 (TGIF1) is a transcriptional repressor of TGF β signaling. Phosphorylated TGIF1 was found to be targeted for degradation by Fbxw7. Fbxw7 is the substrate recognition component of a ubiquitin ligase complex which was found to target proteins such as




Figure 3. Positive regulation of TGF β signaling by Arkadia. TGF β signaling is inhibited by I-Smads, in co-operation with various E3 ligases, targeting several components among which the receptor complexes. SnoN and c-Ski inhibit TGF β signaling at a later step by acting as transcriptional co-repressors. Arkadia targets I-Smad (Smad7), SnoN, and c-Ski for degradation, thereby positively regulating signaling.

cyclin E, c-Myc, Notch, and c-Jun for degradation. Fbxw7 stimulates TGF β signaling by inducing the degradation of TGIF1 (46).

Another E3 ligase involved in TGF β regulation is WWP2. The full-length WWP2 (WWP2-FL) was shown to ubiquitinate both Smad2/3 and Smad7. Interestingly, the WWP2-N isoform stimulates the degradation of Smad2/3, yet the WWP-C isoform and WWP2-FL preferentially ubiquitinate Smad7 after TGF β stimulation. These findings imply that depending on the specific isoforms expressed, TGF β signaling can be either activated or inhibited (47).

Ubiquitin as a mediator of non-Smad signaling

TGF β exerts its effects via Smad-dependent and independent pathways. Some of the downstream functions of TGF β signaling are dependent on the ubiquitin system. TGF β was recently found to induce the ubiquitination and subsequent proteasomal degradation of Krüppel-like factor 4 (KLF4). KLF4 is a transcription factor involved in the regulation of core cell functions such as proliferation, differentiation, and apoptosis, and it has been implicated in carcinogenesis. TGF β signaling induces the ubiquitination of KLF4 by Cdh1/APC, and this pathway is important for TGF β -mediated transcription regulation (48).

Besides its function in regulating protein levels of TGF β signaling components, Smurf1 has also been shown to function downstream of TGF β as a regulator of RhoA signaling (49). TGF β is known to affect the RhoA pathway, and this is important for TGF β -induced EMT. Activated T β RII phosphorylates Par6, which then interacts with Smurf1. Smurf1 subsequently targets RhoA for degradation, and this loss of RhoA leads to hallmarks of EMT, such as the loss of tight junctions and cell polarity (50). Furthermore, Smurf1 was shown to be phosphorylated, thereby its substrate preference switched from Par6 to RhoA (51). The importance of Smurfs in the regulation of cell polarity, involving Par6 and a non-canonical Wnt pathway, is becoming increasingly clear (52,53).

Smurfs also mediate TGF β anti-inflammatory signals together with Smad6 by targeting MyD88 for degradation (54). Smurf1 has been implicated in the regulation of inflammation due to its ability to ubiquitinate TNF receptor associated factors (TRAFs) (55,56). Smurf2 was found to associate with TRAF2 and ubiquitinate TNF receptor 2, thereby affecting downstream signaling (57). It is becoming clear that E3 ligases such as Smurfs do not just regulate a single pathway; rather they function as the effectors of various types of regulation, depending on their recruitment by other proteins. Together with I-Smads they inhibit the TGF β pathway, yet other adaptors

may recruit them to other pathways, such as RhoA and TRAFs. The substrate specificity of E3 ligases, such as Smurf1, can be regulated by post-translational modifications and cellular localization (51,58). A single E3 ligase can therefore have different functions depending on cellular context.

Role of DUBs in TGF β signaling

DUBs remove Ub chains or mono-ubiquitin modifications from target proteins, thereby counteracting the function of E3 ligases. They show specificity for the type of Ub modification and the substrate, yet generally they are less specific than E3 ligases. Some DUBs have been identified to target components of the TGF β pathway. One such DUB is UCH37, which was shown to bind to Smad7 and deubiquitinate T β RI (59). It stabilizes the type I receptor and can therefore be regarded as the counterpart of E3 ligases such as Smurfs in regulating TGF β receptor expression. UCH37 enhances early signaling and is important for TGF β -induced migration (60). CYLD was shown to be involved in the regulation of TGF β signaling in T cells. CYLD is a DUB that preferentially hydrolyses K63 chains and is known to inhibit JNK and NF- κ B signaling. CYLD deubiquitinates Smad7 and thereby inhibits the activation of TAK1 and p38, thus inhibiting the TGF β -induced development of regulatory T cells (61). Recently, USP15 was shown to deubiquitinate mono-ubiquitinated R-Smads (62). The mono-ubiquitination of R-Smads inhibits DNA binding, therefore USP15 is required for proper TGF β signaling.

Two other DUBs that have been implicated in TGF β signal transduction are AMSH, associated molecule with the SH3 (Src homology 3) domain of SA (signal-transducing adaptor molecule) (63), and AMSH-like protein (AMSH-LP). They were shown to associate with I-Smads and inhibit their function, thereby potentiating BMP and TGF β signaling (64,65). Furthermore, AMSH was shown to be ubiquitinated by Smurf2 via RNF11 recruitment (66). These DUBs preferentially cleave K63-linked Ub chains (67), yet this DUB activity has not been confirmed to be necessary for affecting TGF β signaling. AMSH has been described to function in the regulation of receptor turnover by the endosomal sorting complexes required for transport (ESCRT) machinery (68). It is unclear what its targets are precisely, yet a role in receptor trafficking implies a more general function in cell signaling.

Non-degradative ubiquitin modifications in TGF β signaling

As previously discussed, not all forms of ubiquitination lead to proteasomal degradation of the target




Figure 4. Mono-ubiquitination of Smad4. Active complexes of Co-Smad, Smad4, and phosphorylated R-Smads recruit histone acetyltransferases (HATs) to chromatin. The acetylation of histones recruits Ectoderm/TIF1γ (Ecto), which then disrupts Smad complexes and mono-ubiquitinates the Co-Smad. Released R-Smads are most likely dephosphorylated and exported to the cytoplasm. Ubiquitinated Smad4 is exported to the cytoplasm, where the deubiquitinating enzyme (DUB) FAM/USP9x removes the ubiquitin moiety. Smad4 is now ready once again to form complexes with R-Smads.

protein. Other types of Ub modifications, such as mono-ubiquitination or K11 and K63 chains, serve to alter the activation state of the protein, its subcellular localization, or its ability to form protein–protein

interactions. In the TGFβ signaling pathway various examples of these types of post-translational modifications have been identified, which demonstrate the biological importance of this ‘alternative side’ of the ubiquitin system.




Figure 5. TRAF6 activates TAK1. Tumor necrosis factor receptor (TNFR)-associated factor 6 (TRAF6) binds activated TGFβ receptor complexes and is activated via K63 autoubiquitination. TRAF6 subsequently ubiquitinates and activates TGFβ-associated kinase (TAK1), which is responsible for activating non-Smad pathways such as the p38 MAP kinase pathway.

Modulating Smad2 phosphorylation

One of the first steps in the canonical TGFβ pathway is the phosphorylation of R-Smads by the TβRI. The efficiency of this activation step was shown to be modulated via ubiquitination. Athlopin 1-interacting protein 4 (AIP4) or Itch was shown to ubiquitinate Smad2 and thereby promote the phosphorylation of Smad2 by TβRI. This results in an enhancement of TGFβ signaling (69). E3 ligase Cbl-b is thought to have a similar function in T cells, since its loss reduces TGFβ-induced Smad2 phosphorylation (70,71). AIP4/Itch was also shown to bind Smad7 and recruit it to TβRI, thereby coupling Smad2 phosphorylation to signal inhibition.

Smad4 mono-ubiquitination

Activated Smad complexes, containing Smad4, translocate to the nucleus and bind to the promoter regions of target genes. They recruit other factors, such as histone acetyltransferases (HATs) p300/CBP to the

Table I. An overview of ubiquitin modifications involved in TGF β signaling.

Target	E3 ligase/ DUB	Adaptor	Comments	References
Negative regulation				
T β RI	Smurf1	Smad6/7, FKBP12		(10,11,95)
	Smurf2	Smad7		(12)
	NEDD4-2	Smad7		(16)
	WWP1	Smad7		(15)
Smad1/Smad5	Smurf1	LMP-1, Smad6/7		(11,17,96)
Smad1	Smurf2			(19)
	CHIP			(32)
Smad2	Smurf2			(18,97)
	NEDD4-2			(16)
	WWP1	TGIF		(98)
Smad3	WWP2-FL	WWP2-N		
	CHIP			(20)
	ROC1-SCF ^{Fbw1a}			(26)
Smad4	WWP2-FL	WWP2-N		(47)
	Smurf1, Smurf2, NEDD4-2, WWP1	Smad2/6/7		(30)
	CHIP			(32)
Smad4	SCF ^{β-TrCp1}			(33)
	SCF ^{Skp2}		Smad4 mutants	(99)
	Positive regulation			
Smad7	Smurf1/2		Affected by acetylation	(10,12,83,85)
	Arkadia	Axin		(37,45)
	WWP2-FL, WWP2-C			(47)
SnoN	Arkadia			(38,89)
	Smurf2	Smad2		(42)
	APC	Smad2/3		(43,100)
TGIF	Fbxw7			(46)
Examples of ubiquitin-mediated non-Smad signaling				
KLF4	Cdh1/APC		Induced by TGF β	(48)
Par6	Smurf1			(51)
RhoA	Smurf1			(50-52,101)
MyD88	Smurf1/2	Smad6		(54)
TRAFs	Smurf1			(55,56)
TNFR2	Smurf2	TRAF2		(57)
DUBs in TGF β signaling				
T β RI	UCH37			(59,60)
Smad1/2/3	USP15			(62)
Smad6	AMSH		Requirement of DUB activity not confirmed	(64)
Smad2/7	AMSH-LP		Requirement of DUB activity not confirmed	(65)
Smad7	CYLD		DUB removing K63	(61)
Non-degradative Ub modifications				
Smad2	AIP4/Itch		Increased Smad2 phosphorylation	(69)
	Cbl-b		Increased Smad2 phosphorylation. Not confirmed	(70,71)

Table I. (Continued).

Target	E3 ligase/ DUB	Adaptor	Comments	References
Smad4	Ectoderm/TIF1 γ	Acetylated histones	Mono-Ub disrupting complex with Smad2	(72,75,76)
	FAM/USP9x		DUB removing mono-Ub	(75)
TAK1	TRAF6		K63 activation	(77)
	USP4		DUB	(78)

chromatin to promote transcription. The acetylation of histones is thought to increase their affinity for proteins such as Ectoderm/TIF1 γ , an E3 ligase. Bound to chromatin, Ectoderm/TIF1 γ is activated to mono-ubiquitinate Smad4 at K519, and this disrupts the association of Smad4 with phospho-Smad2 (72,73). Mono-ubiquitinated Smad4 is exported to the cytoplasm (74). FAM/USP9x is a DUB that counteracts the mono-ubiquitination of Smad4. FAM/USP9x activity is required for Smad4-mediated TGF β signaling, because it re-enables Smad4 to form complexes with R-Smads and signal in the nucleus (75). This mechanism shows a feedback loop where active Smad complexes on chromatin indirectly recruit an E3 ligase to terminate signaling (Figure 4). Moreover, the duration of Smad-chromatin binding can be regulated by the efficiency of this system. Inhibition of TGF β signaling by Ectoderm/TIF1 γ is important *in vivo* during embryonic development (72,76).

The role of TRAF6

Tumor necrosis factor receptor (TNFR)-associated factor 6 (TRAF6) is a ubiquitin E3 ligase, which preferentially conjugates K63 Ub chains onto its substrates. TRAF6 interacts with T β RI and is activated via autoubiquitination, induced by TGF β ligand binding to the receptors. Active TRAF6 ubiquitinates and thereby activates TGF β -associated kinase (TAK1), which is important for the TGF β -induced activation of the p38 MAP kinase pathway (Figure 5) (77). TAK1 is ubiquitinated by TRAF6 but also by TRAF2 in the TNF α pathway. Ubiquitin-specific peptidase 4 (USP4) is a DUB for TAK1 and was found to inhibit TNF α and TGF β -induced NF- κ B activation (78). This mechanism shows how the ubiquitin system can function in the cross-talk between pathways. In cancer cells, TRAF6 was also shown to ubiquitinate T β RI upon TGF β stimulation. T β RI is subsequently cleaved by TNF α -converting enzyme (TACE), and this action creates an intracellular domain of T β RI, which functions in transcriptional complexes in the nucleus to induce the

expression of EMT-related genes such as Snail and MMP2 (79). These activities of TRAF6 involve the tumor-promoting arm of TGF β signaling.

Concluding remarks

TGF β is not only regulated via ubiquitination, it also relies on ubiquitination for its effect on other pathways. The ubiquitin system is a major tool for various pathways to regulate downstream mediators or other signaling pathways. E3 ligases show target specificity; yet their action *in vivo* is dependent on other proteins to act as adaptors or activators, and the specificity of E3 ligases is also dependent on the E2 enzyme providing the Ub moiety (5,49). Most E3 ligases discussed in this review have also been shown to target components of other signaling pathways.

This review focuses on ubiquitin modifications, yet other modifications such as the conjugation of small ubiquitin-like modifier (SUMO) onto TGF β signaling components have also been found to be important. Both receptors and Smads have been shown to be SUMOylated, affecting their function (80-82). Different modifications, such as phosphorylation, acetylation, SUMOylation, and ubiquitination, can affect each other by recruiting enzymes, or they can compete with each other for binding sites. One clear example of this interplay between modifications in TGF β signaling is the regulation of Smad7 stability. Smad7 was found to be acetylated by p300 on two lysine residues (83). These are the same residues Smurf1 uses to conjugate ubiquitin chains onto Smad7 to target it for degradation. SIRT1 is a deacetylase that counteracts the acetylation of Smad7, making the lysine residues available for ubiquitination (84). Acetylation and ubiquitination thereby compete in regulating Smad7 stability (85). In summary, the real story is longer than presented here, and with the identification of new targets, adaptors, and enzymes the overall picture is becoming increasingly complex. An overview of ubiquitin modifications discussed in this review can be found in Table I.

As disruptions in TGF β signal transduction are implicated in a wide variety of cancers and the

ubiquitin system is important for the regulation of this pathway, it does not come as a surprise that in several cancers dysregulations of E3 ligases such as Smurfs and Arkadia have been found (86,87). In various tumors, increased Smurf expression leads to decreased Smad levels, and this affects tumor progression and correlates with poor prognosis (88). A loss of Smad4 expression is a common finding in many cancers. This loss can be caused by mutations which make it more prone to ubiquitination, thereby destabilizing Smad4 (34,35). In some tumors, TGF β signaling is inhibited by the over-expression of a transcriptional co-repressor such as SnoN. This over-expression of SnoN was found to be caused by a loss of Arkadia and thereby a lack of Arkadia-mediated SnoN degradation. A restoration of Arkadia expression rescued TGF β signaling in these cells (89,90). A loss of Fbxw7 and subsequent increase in TGIF1 expression has also been implicated in cancer (46). E3 ligases, and also DUBs (91), therefore represent a new class of potential oncogenes and tumor suppressors.

The ubiquitin system can be targeted pharmacologically at different levels. The only drug now being used in the clinic is bortezomib, a general proteasome inhibitor. This drug has cytotoxic effects due to the non-specific inhibition of protein degradation. It is prescribed for multiple myeloma and mantle cell lymphoma, and more proteasome inhibitors are currently under investigation as anti-cancer drugs. Yet the ubiquitin system has the potential of providing us with specific drug targets (92,93). Small molecule E3 ligase inhibitors can potentially rescue specific proteins from proteasomal degradation. An example currently being investigated is the E3 ligase MDM2, which targets the tumor suppressor p53 for degradation. But also Smurfs are interesting targets, as they are found to be over-expressed in certain cancers. DUBs are proteases and are therefore more easily targeted specifically by inhibitors. Some DUB inhibitors, such as inhibitors of USP7, are being investigated as anti-cancer drugs. Small molecule inhibitors targeting E3 ligases or DUBs involved in the regulation of TGF β signaling could prove useful in counteracting perturbations in TGF β signaling commonly found in cancer cells.

Acknowledgements

We apologize to the authors of those papers we were not able to cite due to space limitations. We would like to thank Alfred Vertegaal for critical reading of this review. Research on ubiquitin-mediated regulation of TGF β signaling in our laboratory is supported by the Centre for Biomedical Genetics, Netherlands

organization for scientific research (NWO), and Cancerfonden (Contract Number: 09 0773). Miriam de Boeck is supported by the LUMC grant for excellent students in Biomedical Sciences.

Declaration of interest: The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

References

1. Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF- β family signalling. *Nature*. 2003;425:577–84.
2. Mu Y, Gudey SK, Landstrom M. Non-Smad signaling pathways. *Cell Tissue Res*. 2012;347:11–20.
3. Bandyopadhyay B, Han A, Dai J, Fan J, Li Y, Chen M, et al. T β RI/Alk5-independent T β RII signaling to ERK1/2 in human skin cells according to distinct levels of T β RII expression. *J Cell Sci*. 2011;124:19–24.
4. Komander D, Clague MJ, Urbe S. Breaking the chains: structure and function of the deubiquitinases. *Nat Rev Mol Cell Biol*. 2009;10:550–63.
5. Hershko A, Ciechanover A. The ubiquitin system. *Annu Rev Biochem*. 1998;67:425–79.
6. Behrends C, Harper JW. Constructing and decoding unconventional ubiquitin chains. *Nat Struct Mol Biol*. 2011;18:520–8.
7. Hayashi H, Abdollah S, Qiu Y, Cai J, Xu YY, Grinnell BW, et al. The MAD-related protein Smad7 associates with the TGF β receptor and functions as an antagonist of TGF β signaling. *Cell*. 1997;89:1165–73.
8. Imamura T, Takase M, Nishihara A, Oeda E, Hanai J, Kawabata M, et al. Smad6 inhibits signalling by the TGF- β superfamily. *Nature*. 1997;389:622–6.
9. Wiesner S, Ogunjimi AA, Wang HR, Rotin D, Sicheri F, Wrana JL, et al. Autoinhibition of the HECT-type ubiquitin ligase Smurf2 through its C2 domain. *Cell*. 2007;130:651–62.
10. Ebisawa T, Fukuchi M, Murakami G, Chiba T, Tanaka K, Imamura T, et al. Smurf1 interacts with transforming growth factor- β type I receptor through Smad7 and induces receptor degradation. *J Biol Chem*. 2001;276:12477–80.
11. Murakami G, Watabe T, Takaoka K, Miyazono K, Imamura T. Cooperative inhibition of bone morphogenetic protein signaling by Smurf1 and inhibitory Smads. *Mol Biol Cell*. 2003;14:2809–17.
12. Kavsak P, Rasmussen RK, Causing CG, Bonni S, Zhu H, Thomsen GH, et al. Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF β receptor for degradation. *Mol Cell*. 2000;6:1365–75.
13. Finnson KW, Tam BY, Liu K, Marcoux A, Lepage P, Roy S, et al. Identification of CD109 as part of the TGF- β receptor system in human keratinocytes. *FASEB J*. 2006;20:1525–7.
14. Bizet AA, Tran-Khanh N, Saksena A, Liu K, Buschmann MD, Philip A. CD109-mediated degradation of TGF- β receptors and inhibition of TGF- β responses involve regulation of SMAD7 and Smurf2 localization and function. *J Cell Biochem*. 2012;113:238–46.
15. Komuro A, Imamura T, Saitoh M, Yoshida Y, Yamori T, Miyazono K, et al. Negative regulation of transforming growth factor- β (TGF- β) signaling by WW domain-containing protein 1 (WWP1). *Oncogene*. 2004;23:6914–23.

16. Kuratomi G, Komuro A, Goto K, Shinozaki M, Miyazawa K, Miyazono K, et al. NEDD4-2 (neural precursor cell expressed, developmentally down-regulated 4-2) negatively regulates TGF- β (transforming growth factor- β) signalling by inducing ubiquitin-mediated degradation of Smad2 and TGF- β type I receptor. *Biochem J.* 2005;386:461–70.
17. Zhu H, Kavsak P, Abdollah S, Wrana JL, Thomsen GH. A SMAD ubiquitin ligase targets the BMP pathway and affects embryonic pattern formation. *Nature.* 1999;400:687–93.
18. Lin X, Liang M, Feng XH. Smurf2 is a ubiquitin E3 ligase mediating proteasome-dependent degradation of Smad2 in transforming growth factor- β signaling. *J Biol Chem.* 2000;275:36818–22.
19. Zhang Y, Chang C, Gehling DJ, Hemmati-Brivanlou A, Derynck R. Regulation of Smad degradation and activity by Smurf2, an E3 ubiquitin ligase. *Proc Natl Acad Sci U S A.* 2001;98:974–9.
20. Xin H, Xu X, Li L, Ning H, Rong Y, Shang Y, et al. CHIP controls the sensitivity of transforming growth factor- β signaling by modulating the basal level of Smad3 through ubiquitin-mediated degradation. *J Biol Chem.* 2005;280:20842–50.
21. Wang L, Liu YT, Hao R, Chen L, Chang Z, Wang HR, et al. Molecular mechanism of the negative regulation of Smad1/5 protein by carboxyl terminus of Hsc70-interacting protein (CHIP). *J Biol Chem.* 2011;286:15883–94.
22. Guo X, Ramirez A, Waddell DS, Li Z, Liu X, Wang XF. Axin and GSK3- β control Smad3 protein stability and modulate TGF- β signaling. *Genes Dev.* 2008;22:106–20.
23. Fuentelba LC, Eivers E, Ikeda A, Hurtado C, Kuroda H, Pera EM, et al. Integrating patterning signals: Wnt/GSK3 regulates the duration of the BMP/Smad1 signal. *Cell.* 2007;131:980–93.
24. Nakano A, Koinuma D, Miyazawa K, Uchida T, Saitoh M, Kawabata M, et al. Pin1 down-regulates transforming growth factor- β (TGF- β) signaling by inducing degradation of Smad proteins. *J Biol Chem.* 2009;284:6109–15.
25. Gao S, Alarcon C, Sapkota G, Rahman S, Chen PY, Goerner N, et al. Ubiquitin ligase Nedd4L targets activated Smad2/3 to limit TGF- β signaling. *Mol Cell.* 2009;36:457–68.
26. Fukuchi M, Imamura T, Chiba T, Ebisawa T, Kawabata M, Tanaka K, et al. Ligand-dependent degradation of Smad3 by a ubiquitin ligase complex of ROC1 and associated proteins. *Mol Biol Cell.* 2001;12:1431–43.
27. Alarcon C, Zaromytidou AI, Xi Q, Gao S, Yu J, Fujisawa S, et al. Nuclear CDKs drive Smad transcriptional activation and turnover in BMP and TGF- β pathways. *Cell.* 2009;139:757–69.
28. Aragon E, Goerner N, Zaromytidou AI, Xi Q, Escobedo A, Massague J, et al. A Smad action turnover switch operated by WW domain readers of a phosphoserine code. *Genes Dev.* 2011;25:1275–88.
29. Mavrakis KJ, Andrew RL, Lee KL, Petropoulou C, Dixon JE, Navaratnam N, et al. Arkadia enhances Nodal/TGF- β signaling by coupling phospho-Smad2/3 activity and turnover. *PLoS Biol.* 2007;5:67.
30. Moren A, Imamura T, Miyazono K, Heldin CH, Moustakas A. Degradation of the tumor suppressor Smad4 by WW and HECT domain ubiquitin ligases. *J Biol Chem.* 2005;280:22115–23.
31. Wan M, Cao X, Wu Y, Bai S, Wu L, Shi X, et al. Jab1 antagonizes TGF- β signaling by inducing Smad4 degradation. *EMBO Rep.* 2002;3:171–6.
32. Li L, Xin H, Xu X, Huang M, Zhang X, Chen Y, et al. CHIP mediates degradation of Smad proteins and potentially regulates Smad-induced transcription. *Mol Cell Biol.* 2004;24:856–64.
33. Wan M, Tang Y, Tytler EM, Lu C, Jin B, Vickers SM, et al. Smad4 protein stability is regulated by ubiquitin ligase SCF β -TrCP1. *J Biol Chem.* 2004;279:14484–7.
34. Yang L, Wang N, Tang Y, Cao X, Wan M. Acute myelogenous leukemia-derived SMAD4 mutations target the protein to ubiquitin-proteasome degradation. *Hum Mutat.* 2006;27:897–905.
35. Wan M, Huang J, Jhala NC, Tytler EM, Yang L, Vickers SM, et al. SCF(β -TrCP1) controls Smad4 protein stability in pancreatic cancer cells. *Am J Pathol.* 2005;166:1379–92.
36. Ito I, Hanyu A, Wayama M, Goto N, Katsuno Y, Kawasaki S, et al. Estrogen inhibits transforming growth factor β signaling by promoting Smad2/3 degradation. *J Biol Chem.* 2010;285:14747–55.
37. Koinuma D, Shinozaki M, Komuro A, Goto K, Saitoh M, Hanyu A, et al. Arkadia amplifies TGF- β superfamily signalling through degradation of Smad7. *EMBO J.* 2003;22:6458–70.
38. Nagano Y, Mavrakis KJ, Lee KL, Fujii T, Koinuma D, Sase H, et al. Arkadia induces degradation of SnoN and c-Ski to enhance transforming growth factor- β signaling. *J Biol Chem.* 2007;282:20492–501.
39. Wu JW, Krawitz AR, Chai J, Li W, Zhang F, Luo K, et al. Structural mechanism of Smad4 recognition by the nuclear oncoprotein Ski: insights on Ski-mediated repression of TGF- β signaling. *Cell.* 2002;111:357–67.
40. Suzuki H, Yagi K, Kondo M, Kato M, Miyazono K, Miyazawa K. C-Ski inhibits the TGF- β signaling pathway through stabilization of inactive Smad complexes on Smad-binding elements. *Oncogene.* 2004;23:5068–76.
41. Tabata T, Kokura K, Ten Dijke P, Ishii S. Ski co-repressor complexes maintain the basal repressed state of the TGF- β target gene, SMAD7, via HDAC3 and PRMT5. *Genes Cells.* 2009;14:17–28.
42. Bonni S, Wang HR, Causing CG, Kavsak P, Stroschein SL, Luo K, et al. TGF- β induces assembly of a Smad2-Smurf2 ubiquitin ligase complex that targets SnoN for degradation. *Nat Cell Biol.* 2001;3:587–95.
43. Stroschein SL, Bonni S, Wrana JL, Luo K. Smad3 recruits the anaphase-promoting complex for ubiquitination and degradation of SnoN. *Genes Dev.* 2001;15:2822–36.
44. Koinuma D, Shinozaki M, Nagano Y, Ikushima H, Horiguchi K, Goto K, et al. RB1CC1 positively regulates transforming growth factor- β signaling through the modulation of Arkadia E3 ubiquitin ligase activity. *J Biol Chem.* 2011;286:32502–12.
45. Liu W, Rui H, Wang J, Lin S, He Y, Chen M, et al. Axin is a scaffold protein in TGF- β signaling that promotes degradation of Smad7 by Arkadia. *EMBO J.* 2006;25:1646–58.
46. Bengoechea-Alonso MT, Ericsson J. Tumor suppressor Fbxw7 regulates TGF β signaling by targeting TGIF1 for degradation. *Oncogene.* 2010;29:5322–8.
47. Soond SM, Chantry A. Selective targeting of activating and inhibitory Smads by distinct WWP2 ubiquitin ligase isoforms differentially modulates TGF β signalling and EMT. *Oncogene.* 2011;30:2451–62.
48. Hu D, Wan Y. Regulation of Kruppel-like factor 4 by the anaphase promoting complex pathway is involved in TGF- β signaling. *J Biol Chem.* 2011;286:6890–901.
49. Andrews PS, Schneider S, Yang E, Michaels M, Chen H, Tang J, et al. Identification of substrates of SMURF1 ubiquitin ligase activity utilizing protein microarrays. *Assay Drug Dev Technol.* 2010;8:471–87.
50. Ozdamar B, Bose R, Barrios-Rodiles M, Wang HR, Zhang Y, Wrana JL. Regulation of the polarity protein Par6 by TGF β

- receptors controls epithelial cell plasticity. *Science*. 2005;307:1603–9.
51. Cheng PL, Lu H, Shelly M, Gao H, Poo MM. Phosphorylation of E3 ligase Smurf1 switches its substrate preference in support of axon development. *Neuron*. 2011;69:231–43.
 52. Tian M, Bai C, Lin Q, Lin H, Liu M, Ding F, et al. Binding of RhoA by the C2 domain of E3 ligase Smurf1 is essential for Smurf1-regulated RhoA ubiquitination and cell protrusive activity. *FEBS Lett*. 2011;585:2199–204.
 53. Narimatsu M, Bose R, Pye M, Zhang L, Miller B, Ching P, et al. Regulation of planar cell polarity by Smurf ubiquitin ligases. *Cell*. 2009;137:295–307.
 54. Lee YS, Park JS, Kim JH, Jung SM, Lee JY, Kim SJ, et al. Smad6-specific recruitment of Smurf E3 ligases mediates TGF- β 1-induced degradation of MyD88 in TLR4 signalling. *Nat Commun*. 2011;2:460.
 55. Kalkan T, Iwasaki Y, Park CY, Thomsen GH. Tumor necrosis factor-receptor-associated factor-4 is a positive regulator of transforming growth factor- β signaling that affects neural crest formation. *Mol Biol Cell*. 2009;20:3436–50.
 56. Li S, Lu K, Wang J, An L, Yang G, Chen H, et al. Ubiquitin ligase Smurf1 targets TRAF family proteins for ubiquitination and degradation. *Mol Cell Biochem*. 2010;338:11–17.
 57. Carpentier I, Coornaert B, Beyaert R. Smurf2 is a TRAF2 binding protein that triggers TNF-R2 ubiquitination and TNF-R2-induced JNK activation. *Biochem Biophys Res Commun*. 2008;374:752–7.
 58. Lu K, Li P, Zhang M, Xing G, Li X, Zhou W, et al. Pivotal role of the C2 domain of the Smurf1 ubiquitin ligase in substrate selection. *J Biol Chem*. 2011;286:16861–70.
 59. Wicks SJ, Haros K, Maillard M, Song L, Cohen RE, Dijke PT, et al. The deubiquitinating enzyme UCH37 interacts with Smads and regulates TGF- β signalling. *Oncogene*. 2005;24:8080–4.
 60. Cutts AJ, Soond SM, Powell S, Chantry A. Early phase TGF β receptor signalling dynamics stabilised by the deubiquitinase UCH37 promotes cell migratory responses. *Int J Biochem Cell Biol*. 2011;43:604–12.
 61. Zhao Y, Thornton AM, Kinney MC, Ma CA, Spinner JJ, Fuss IJ, et al. The deubiquitinase CYLD targets Smad7 to regulate TGF- β signaling and the development of regulatory T cells. *J Biol Chem*. 2011;286:40520–30.
 62. Inui M, Manfrin A, Mamidi A, Martello G, Morsut L, Soligo S, et al. USP15 is a deubiquitylating enzyme for receptor-activated SMADs. *Nat Cell Biol*. 2011;13:1368–75.
 63. Tanaka N, Kaneko K, Asao H, Kasai H, Endo Y, Fujita T, et al. Possible involvement of a novel STAM-associated molecule "AMSH" in intracellular signal transduction mediated by cytokines. *J Biol Chem*. 1999;274:19129–35.
 64. Itoh F, Asao H, Sugamura K, Heldin CH, Ten Dijke P, Itoh S. Promoting bone morphogenetic protein signaling through negative regulation of inhibitory Smads. *EMBO J*. 2001;20:4132–42.
 65. Ibarrola N, Kratchmarova I, Nakajima D, Schiemann WP, Moustakas A, Pandey A, et al. Cloning of a novel signaling molecule, AMSH-2, that potentiates transforming growth factor β signaling. *BMC Cell Biol*. 2004;5:2.
 66. Li H, Seth A. An RNF11: Smurf2 complex mediates ubiquitination of the AMSH protein. *Oncogene*. 2004;23:1801–8.
 67. Sato Y, Yoshikawa A, Yamagata A, Mimura H, Yamashita M, Ookata K, et al. Structural basis for specific cleavage of Lys 63-linked polyubiquitin chains. *Nature*. 2008;455:358–62.
 68. Clague MJ, Urbe S. Endocytosis: the DUB version. *Trends Cell Biol*. 2006;16:551–9.
 69. Bai Y, Yang C, Hu K, Elly C, Liu YC. Itch E3 ligase-mediated regulation of TGF- β signaling by modulating smad2 phosphorylation. *Mol Cell*. 2004;15:825–31.
 70. Wohlfert EA, Gorelik L, Mittler R, Flavell RA, Clark RB. Cutting edge: deficiency in the E3 ubiquitin ligase Cbl-b results in a multifunctional defect in T cell TGF- β sensitivity in vitro and in vivo. *J Immunol*. 2006;176:1316–20.
 71. Adams CO, Housley WJ, Bhowmick S, Cone RE, Rajan TV, Forouhar F, et al. Cbl-b(-/-) T cells demonstrate in vivo resistance to regulatory T cells but a context-dependent resistance to TGF- β . *J Immunol*. 2010;185:2051–8.
 72. Dupont S, Zacchigna L, Cordenonsi M, Soligo S, Adorno M, Rugge M, et al. Germ-layer specification and control of cell growth by Ectodermin, a Smad4 ubiquitin ligase. *Cell*. 2005;12:87–99.
 73. Agricola E, Randall RA, Gaarenstroom T, Dupont S, Hill CS. Recruitment of TIF1gamma to chromatin via its PHD finger-bromodomain activates its ubiquitin ligase and transcriptional repressor activities. *Mol Cell*. 2011;43:85–96.
 74. Wang B, Suzuki H, Kato M. Roles of mono-ubiquitinated Smad4 in the formation of Smad transcriptional complexes. *Biochem Biophys Res Commun*. 2008;376:288–92.
 75. Dupont S, Mamidi A, Cordenonsi M, Montagner M, Zacchigna L, Adorno M, et al. FAM/USP9x, a deubiquitinating enzyme essential for TGF β signaling, controls Smad4 monoubiquitination. *Cell*. 2009;136:123–35.
 76. Morsut L, Yan KP, Enzo E, Aragona M, Soligo SM, Wendling O, et al. Negative control of Smad activity by ectodermin/Tif1gamma patterns the mammalian embryo. *Development*. 2010;137:2571–8.
 77. Sorrentino A, Thakur N, Grimsby S, Marcusson A, von Bulow V, Schuster N, et al. The type I TGF- β receptor engages TRAF6 to activate TAK1 in a receptor kinase-independent manner. *Nat Cell Biol*. 2008;10:1199–207.
 78. Fan YH, Yu Y, Mao RF, Tan XJ, Xu GF, Zhang H, et al. USP4 targets TAK1 to downregulate TNF α -induced NF- κ B activation. *Cell Death Differ*. 2011;18:1547–60.
 79. Mu Y, Sundar R, Thakur N, Ekman M, Gudey SK, Yakymovych M, et al. TRAF6 ubiquitinates TGF β type I receptor to promote its cleavage and nuclear translocation in cancer. *Nat Commun*. 2011;2:330.
 80. Lee PS, Chang C, Liu D, Derynck R. Sumoylation of Smad4, the common Smad mediator of transforming growth factor- β family signaling. *J Biol Chem*. 2003;278:27853–63.
 81. Lin X, Liang M, Liang YY, Brunicaudi FC, Melchior F, Feng XH. Activation of transforming growth factor- β signaling by SUMO-1 modification of tumor suppressor Smad4/DPC4. *J Biol Chem*. 2003;278:18714–19.
 82. Kang JS, Saunier EF, Akhurst RJ, Derynck R. The type I TGF- β receptor is covalently modified and regulated by sumoylation. *Nat Cell Biol*. 2008;10:654–64.
 83. Gronroos E, Hellman U, Heldin CH, Ericsson J. Control of Smad7 stability by competition between acetylation and ubiquitination. *Mol Cell*. 2002;10:483–93.
 84. Kume S, Haneda M, Kanasaki K, Sugimoto T, Araki S, Isshiki K, et al. SIRT1 inhibits transforming growth factor β -induced apoptosis in glomerular mesangial cells via Smad7 deacetylation. *J Biol Chem*. 2007;282:151–8.
 85. Simonsson M, Heldin CH, Ericsson J, Gronroos E. The balance between acetylation and deacetylation controls Smad7 stability. *J Biol Chem*. 2005;280:21797–803.
 86. Hellwinkel OJ, Asong LE, Rogmann JP, Sultmann H, Wagner C, Schlomm T, et al. Transcription alterations of members of the ubiquitin-proteasome network in prostate carcinoma. *Prostate Cancer Prostatic Dis*. 2011;14:38–45.

87. Fukasawa H, Yamamoto T, Fujigaki Y, Misaki T, Ohashi N, Takayama T, et al. Reduction of transforming growth factor- β type II receptor is caused by the enhanced ubiquitin-dependent degradation in human renal cell carcinoma. *Int J Cancer*. 2010; 127:1517–25.
88. Kwei KA, Shain AH, Bair R, Montgomery K, Karikari CA, van de Rijn M, et al. SMURF1 amplification promotes invasiveness in pancreatic cancer. *PLoS One*. 2011;6:e23924.
89. Levy L, Howell M, Das D, Harkin S, Episkopou V, Hill CS. Arkadia activates Smad3/Smad4-dependent transcription by triggering signal-induced SnoN degradation. *Mol Cell Biol*. 2007;27:6068–83.
90. Nagano Y, Koinuma D, Miyazawa K, Miyazono K. Context-dependent regulation of the expression of c-Ski protein by Arkadia in human cancer cells. *J Biochem*. 2010;147:545–54.
91. Sacco JJ, Coulson JM, Clague MJ, Urbe S. Emerging roles of deubiquitinases in cancer-associated pathways. *IUBMB Life*. 2010;62:140–57.
92. Cohen P, Tcherpakov M. Will the ubiquitin system furnish as many drug targets as protein kinases? *Cell*. 2010;143:686–93.
93. Guedat P, Colland F. Patented small molecule inhibitors in the ubiquitin proteasome system. *BMC Biochem*. 2007;8 (Suppl 1):S14.
94. Heldin CH, Miyazono K, Ten Dijke P. TGF- β signalling from cell membrane to nucleus through SMAD proteins. *Nature*. 1997;390:465–71.
95. Yamaguchi T, Kurisaki A, Yamakawa N, Minakuchi K, Sugino H. FKBP12 functions as an adaptor of the Smad7-Smurfl complex on activin type I receptor. *J Mol Endocrinol*. 2006;36:569–79.
96. Sangadala S, Boden SD, Viggewarapu M, Liu Y, Titus L. LIM mineralization protein-1 potentiates bone morphogenetic protein responsiveness via a novel interaction with Smurfl resulting in decreased ubiquitination of Smads. *J Biol Chem*. 2006;281:17212–19.
97. Lo RS, Massague J. Ubiquitin-dependent degradation of TGF- β -activated smad2. *Nat Cell Biol*. 1999;1:472–8.
98. Seo SR, Lallemand F, Ferrand N, Pessah M, L'Hoste S, Camonis J, et al. The novel E3 ubiquitin ligase Tiul1 associates with TGIF to target Smad2 for degradation. *EMBO J*. 2004;23:3780–92.
99. Liang M, Liang YY, Wrighton K, Ungermannova D, Wang XP, Brunnicardi FC, et al. Ubiquitination and proteolysis of cancer-derived Smad4 mutants by SCFSkp2. *Mol Cell Biol*. 2004;24:7524–37.
100. Wan Y, Liu X, Kirschner MW. The anaphase-promoting complex mediates TGF- β signaling by targeting SnoN for destruction. *Mol Cell*. 2001;8:1027–39.
101. Wang HR, Zhang Y, Ozdamar B, Ogunjimi AA, Alexandrova E, Thomsen GH, et al. Regulation of cell polarity and protrusion formation by targeting RhoA for degradation. *Science*. 2003;302:1775–9.